<DOC>
	<DOCNO>NCT01769768</DOCNO>
	<brief_summary>This multi center , open-label study evaluate drug-drug interaction LDE225 PK bupropion warfarin patient advance solid tumor . Subjects receive 800mg daily LDE225 two separate dos either bupropion warfarin .</brief_summary>
	<brief_title>Phase I Study Evaluate Effect LDE225 Pharmacokinetics Bupropion Warfarin Patients</brief_title>
	<detailed_description />
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Adults Patients cytopathologically histopathologically confirm diagnosis advance solid tumor progress despite standard therapy , standard therapy exist patient locally advance metastatic basal cell carcinoma amendable eligible standard therapy . Protocoldefined renal , liver bone marrow function CNS ( Central Nervous System ) tumor well history brain metastasis Systemic anticancer treatment ( include biologic therapy/antibodies ) within 2 week first dose study treatment ( 6 week nitrosourea , mitomycin , monoclonal antibody ) . Radiation therapy within 4 week first dose Investigational agent within 4 week start study therapy Patients know allergy/hypersensitivity warfarin bupropion and/or related compound Patients history of/or active bleeding disorder Patients receive treatment vitamin K , Coumadin agent contain warfarin heparin . Heparin flush maintain patency central venous access device allow . Patients receive treatment bupropion . Patients neuromuscular disorder associate elevated CK ( Creatine phosphokinase ) ( e.g. , inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) . Known diagnosis human immunodeficiency virus ( HIV ) , Hepatitis B C ( test mandatory study entry ) Patients currently receive systemic corticosteroid Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Adults , Hh ( Hedgehog ) pathway inhibitor , LDE225 , Warfarin , Bupropion , advance solid tumor , drug-drug interaction , pharmacokinetic</keyword>
</DOC>